BioMarin Pharmaceuticals BMRN Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from BioMarin Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's free cash flow yield?
- BioMarin Pharmaceuticals (BMRN) reported free cash flow yield of 7.1% in Q1 2026.
- How has BioMarin Pharmaceuticals's free cash flow yield changed year-over-year?
- BioMarin Pharmaceuticals's free cash flow yield increased by 52.5% year-over-year, from 4.6% to 7.1%.
- What is the long-term trend for BioMarin Pharmaceuticals's free cash flow yield?
- Over 3 years (2020 to 2025), BioMarin Pharmaceuticals's free cash flow yield has grown at a 222.3% compound annual growth rate (CAGR), from -0.2% to 6.3%.
- What does free cash flow yield mean?
- The spendable cash the business throws off each year as a percentage of its market price.
- How do you interpret free cash flow yield?
- Higher yield can mean better value — you pay less for each dollar of cash generated. A useful sanity check against earnings-based multiples, which non-cash items can distort.
- How does free cash flow yield compare across companies?
- Comparable across cash-generative companies; less meaningful for firms in heavy-investment phases with temporarily negative FCF.